Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
暂无分享,去创建一个
J. Pape | E. Gotuzzo | B. Grinsztejn | B. Shepherd | B. Crabtree-Ramírez | Y. Caro-Vega | D. Padgett | C. McGowan | J. Sierra-Madero | M. Wolff | Pablo F Belaunzarán-Zamudio
[1] Tyler J. VanderWeele,et al. Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.
[2] Tania B. Huedo-Medina,et al. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] W. Belloso,et al. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study , 2016, International journal of STD & AIDS.
[4] P. Rebeiro,et al. Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network , 2016, Journal of acquired immune deficiency syndromes.
[5] Richard D Moore,et al. Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America , 2016, Journal of the International AIDS Society.
[6] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[7] H. Jessen,et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. , 2015, The Lancet. Infectious diseases.
[8] Carlos Magis-Rodríguez,et al. Inicio tardío de terapia antirretroviral en México , 2015 .
[9] P. Cahn,et al. Use of Third Line Antiretroviral Therapy in Latin America , 2014, PloS one.
[10] R. Bologna,et al. Manejo de los pacientes adultos con infección por VIH , 2012 .
[11] B. Crabtree-Ramírez,et al. Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART Through Clinical Trials Compared With Routine Care in Mexico , 2012, Journal of acquired immune deficiency syndromes.
[12] M. Hernán,et al. Beyond the intention-to-treat in comparative effectiveness research , 2012, Clinical trials.
[13] G. d’Ettorre,et al. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease , 2011, BMC infectious diseases.
[14] R. Kuchenbecker,et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.
[15] P. Flandre. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.
[16] D. Masys,et al. Cross-Sectional Analysis of Late HAART Initiation in Latin America and the Caribbean: Late Testers and Late Presenters , 2011, PloS one.
[17] J. Willig,et al. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States , 2011, AIDS care.
[18] D. Katzenstein,et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.
[19] D. Podzamczer,et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. , 2010, AIDS research and human retroviruses.
[20] D. Masys,et al. Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America , 2010, PloS one.
[21] J. Montaner,et al. Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico , 2010, Journal of acquired immune deficiency syndromes.
[22] B. Clotet,et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). , 2010, Antiviral research.
[23] D. Masys,et al. Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean , 2009, Journal of acquired immune deficiency syndromes.
[24] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[25] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[26] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[27] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[28] A. Celi. Presentation to care with advanced HIV disease is still a problem in Latin America , 2016 .
[29] J. Caro,et al. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. , 2001, PharmacoEconomics.